Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 12/20 | 0.62 |
| ▸ | KDM1A | O60341 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 8/20 | 0.61 |
| ▸ | MEN1 | O00255 | 4/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | ABCB1 | P08183 | 6/20 | 0.55 |
| ▸ | ABCC1 | P33527 | 4/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2304172 | 0.85 | KDM1A (0.65) | ABCG2KDM1AMAPTMEN1KMT2A | |
| SCHEMBL2232737 | 0.83 | KDM1A (0.81) | ABCG2KDM1AMAPTMEN1KMT2A | |
| SCHEMBL2296451 | 0.81 | MEN1 (0.54) | ABCG2MAPTMEN1KMT2AKDM4E | |
| SCHEMBL2233756 | 0.80 | MAPT (0.62) | ABCG2KDM1AMAPTMEN1KMT2A | |
| SCHEMBL2232116 | 0.80 | ABCG2 (0.81) | ABCG2KDM1AMAPTMEN1KMT2A | |
| SCHEMBL1083981 | 0.80 | KDM1A (0.66) | ABCG2KDM1AMAPTMEN1KMT2A | |
| SCHEMBL16404294 | 0.79 | ABCG2 (0.86) | ABCG2KDM1AMAPTMEN1KMT2A | |
| SCHEMBL2232368 | 0.79 | KDM1A (0.78) | ABCG2KDM1AMAPTMEN1KMT2A | |
| SCHEMBL2233032 | 0.79 | KDM1A (0.78) | ABCG2KDM1AMAPTMEN1KMT2A | |
| SCHEMBL2231161 | 0.78 | KDM1A (0.77) | ABCG2KDM1AMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2528606-B1 | QUINAZOLINE-BASED T CELL PROLIFERATION INHIBITORS | LEVITZKI ALEXANDER (IL) | 2014-09-24 | — | — | EP | disclosed |
| US-8759363-B2 | Quinazoline-based T cell proliferation inhibitors | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2014-06-24 | — | — | US | disclosed |
| US-20130109706-A1 | QUINAZOLINE-BASED T CELL PROLIFERATION INHIBITORS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERSALEM LTD. (IL) | 2013-05-02 | — | — | US | disclosed |
| EP-2528606-A1 | QUINAZOLINE-BASED T CELL PROLIFERATION INHIBITORS | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2012-12-05 | — | — | EP | disclosed |
| WO-2011092695-A1 | QUINAZOLINE-BASED T CELL PROLIFERATION INHIBITORS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109706-A1 | QUINAZOLINE-BASED T CELL PROLIFERATION INHIBITORS | IL2, CD4, NFATC1 | ABCG2 2405/4885KDM1A 2957/4885MAPT 2104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.